Clinical Trial – Idiopathic Pulmonary Fibrosis – Efficacy... - Roche
This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, compared with placebo in …
American Journal of Respiratory and Critical Care Medicine
Feb 14, 2024 · Zinpentraxin alfa (previously known as PRM-151) is a recombinant form of human pentraxin-2 produced in Chinese hamster ovary cells (19) and, like endogenous pentraxin-2, …
PRM-151 for Idiopathic Pulmonary Fibrosis
Also referred to as PTX2, the therapy injected intravenously in patients, is showing promise as an effective anti-fibrotic agent that can be used to target several rare, orphan diseases with unmet …
Fighting fibrosis - Nature
Promedior, a clinical-stage biotechnology company, is developing immunotherapies to treat fibrosis. The company’s lead product candidate is PRM-151, a recombinant form of human …
Long-term treatment with recombinant human pentraxin 2 protein …
Background: Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151, a recombinant human pentraxin 2 protein, in a phase 2 double-blind, randomised controlled trial …
PRM-151 (recombinant human serum amyloid P/pentraxin 2) …
The recent discovery of its ability to regulate certain monocyte differentiation states has identified PTX2 as a novel and potentially powerful antifibrotic agent. A fully recombinant form of the …
PRM-151 Receives FDA Breakthrough Therapy ... - ILD Collaborative
The U.S. Food and Drug Administration has granted breakthrough therapy designation to PRM-151, a compound being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). …
A Study to Evaluate Safety and Effectiveness of PRM-151 to Treat ...
The purpose of this study is to confirm the long-term safety, effectiveness, and pharmacokinetics of PRM-151 in the treatment of eligible patients with IPF who have taken part in Study PRM …
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with ...
May 20, 2014 · This study investigates the potential of PRM in myelofibrosis (MF) to reduce bone marrow (BM) fibrosis and to improve key MF-related disease features including abnormal …
Experimental IPF Therapy PRM-151 to Enter Phase 3 Trials
Jan 8, 2019 · Promedior plans to begin Phase 3 testing of its investigational therapy PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF), now that the U.S. Food and Drug …